All stock lists
Angiodynamics Inc (NASDAQ:ANGO)
US · Delayed Price · Currency is USD
Healthcare · Medical - Instruments & Supplies
11.99-0.36 (-2.91%)
Market cap
$504M
Insider Score
Health Score
Analyst consensus
Listed since
Jun 1, 2004
Website
Insider Score
––Not scored
ANGO Insider Score
Insiders filed in the last 90 days, but none of those trades qualified for scoring — round-trip buys and filings whose price is far off the market are excluded.
ANGO analyst forecast
ANGO analyst consensus
Moderate Buy2 ratings
Buy 2 Hold 0 Sell 0
Based on each firm’s most recent rating in the last 3 months — one vote per firm, so a desk that reiterates weekly does not count three times.
ANGO 12-month price target
$18.00+50.1% upsideaverage of 1 firm
$18.00High
$18.00Low
ANGO ratings mix, last 12 months
Buy Hold Sell
Best analysts covering ANGO
- HC Wainwright & Co.80%success rate · +33.2% avg return · 10 calls
- Canaccord Genuity57%success rate · +18.1% avg return · 7 calls
Measured by us from each firm’s own rating dates and this stock’s split- and dividend-adjusted closes. How we calculate this.
ANGO analyst ratings
| Firm | Price target | Action | ||||
|---|---|---|---|---|---|---|
| — | HC Wainwright & Co. | Buy | — | — | Reiterated | 2026-10-13 |
| H.C. Wainwright | — | $18.00 | +67.1% | — | 2026-10-13 | |
| — | Canaccord Genuity | Buy | — | — | Reiterated | 2026-10-09 |
| — | Canaccord Genuity | Buy | — | — | Reiterated | 2026-07-15 |
| — | HC Wainwright & Co. | Buy | — | — | Reiterated | 2026-07-15 |
| — | Canaccord Genuity | Buy | — | — | Reiterated | 2026-04-06 |
| — | Canaccord Genuity | Buy | — | — | Reiterated | 2025-10-03 |
| — | HC Wainwright & Co. | Buy | — | — | Reiterated | 2025-07-16 |
| — | Canaccord Genuity | Buy | — | — | Reiterated | 2025-07-16 |
| — | HC Wainwright & Co. | Buy | — | — | Reiterated | 2025-04-07 |
| — | HC Wainwright & Co. | Buy | — | — | Reiterated | 2025-01-10 |
| — | Canaccord Genuity | Buy | — | — | Reiterated | 2025-01-09 |
| — | HC Wainwright & Co. | Buy | — | — | Reiterated | 2024-12-10 |
| — | HC Wainwright & Co. | Buy | — | — | Reiterated | 2024-10-04 |
| — | Canaccord Genuity | Buy | — | — | Reiterated | 2024-10-04 |
| — | HC Wainwright & Co. | Buy | — | — | Reiterated | 2024-09-20 |
| — | HC Wainwright & Co. | Buy | — | — | Reiterated | 2024-07-17 |
| — | Canaccord Genuity | Buy | — | — | Reiterated | 2024-07-17 |
| — | HC Wainwright & Co. | Buy | — | — | Reiterated | 2024-05-22 |
| — | Oppenheimer | Outperform | — | — | Upgraded | 2024-04-05 |
| — | Raymond James | Outperform | — | — | Reiterated | 2024-01-09 |
| — | HC Wainwright & Co. | Buy | — | — | Reiterated | 2024-01-08 |
| — | Raymond James | Outperform | — | — | Reiterated | 2023-10-06 |
| — | HC Wainwright & Co. | Buy | — | — | Reiterated | 2023-10-05 |
| — | Canaccord Genuity | Buy | — | — | Reiterated | 2023-10-05 |
| — | Canaccord Genuity | Buy | — | — | Reiterated | 2023-07-13 |
| — | Raymond James | Outperform | — | — | Downgraded | 2023-04-17 |
| — | Raymond James | Strong Buy | — | — | Reiterated | 2023-04-03 |
| — | Raymond James | Strong Buy | — | — | Reiterated | 2023-01-06 |
| — | Raymond James | Strong Buy | — | — | Reiterated | 2022-10-07 |
| — | Raymond James | Strong Buy | — | — | Reiterated | 2022-07-13 |
| — | Canaccord Genuity | Buy | — | — | Upgraded | 2021-10-15 |
| — | Oppenheimer | Perform | — | — | Reiterated | 2021-08-20 |
| — | Canaccord Genuity | Hold | — | — | Reiterated | 2021-07-14 |
| — | Raymond James | Strong Buy | — | — | Reiterated | 2021-07-09 |
| — | Canaccord Genuity | Hold | — | — | Reiterated | 2021-03-31 |
| — | Raymond James | Strong Buy | — | — | Reiterated | 2021-01-08 |
| — | Raymond James | Strong Buy | — | — | Upgraded | 2020-11-25 |
| — | Canaccord Genuity | Hold | — | — | Reiterated | 2020-04-08 |
| — | KeyBanc | Sector Weight | — | — | Downgraded | 2020-04-08 |
| — | Keybanc | Sector Weight | — | — | Downgraded | 2020-04-08 |
| — | KeyBanc | Overweight | — | — | Reiterated | 2019-10-04 |
| — | Keybanc | Overweight | — | — | Reiterated | 2019-10-04 |
| — | Canaccord Genuity | Hold | — | — | Reiterated | 2019-01-07 |
| — | Raymond James | Outperform | — | — | Upgraded | 2018-04-03 |
| — | Canaccord Genuity | Hold | — | — | Reiterated | 2018-04-02 |
| — | Barclays | Equal Weight | — | — | Reiterated | 2017-07-19 |
| — | Barclays | Equal Weight | — | — | Reiterated | 2017-02-08 |
| — | Cantor Fitzgerald | Buy | — | — | Reiterated | 2016-11-04 |
| — | Canaccord Genuity | Hold | — | — | Downgraded | 2016-04-05 |
| — | Raymond James | Market Perform | — | — | Downgraded | 2015-11-10 |
| — | Sidoti & Co. | Neutral | — | — | Reiterated | 2015-09-23 |
| — | KeyBanc | Outperform | — | — | Reiterated | 2015-07-24 |
| — | Raymond James | Outperform | — | — | Reiterated | 2014-07-24 |
| — | Canaccord Genuity | Buy | — | — | Upgraded | 2014-06-19 |
| — | Raymond James | Outperform | — | — | Upgraded | 2014-03-12 |
| — | PiperJaffray | Neutral | — | — | Reiterated | 2013-03-08 |
| — | Piper Sandler | Neutral | — | — | Reiterated | 2013-03-08 |
| — | Canaccord Genuity | Hold | — | — | Reiterated | 2013-01-04 |
| — | Canaccord Genuity | Hold | — | — | Reiterated | 2012-10-09 |
ANGO earnings vs. estimates
| Quarter | EPS est. | EPS actual | Revenue est. | Revenue actual |
|---|---|---|---|---|
| 2026-01-06 | -0.10 | -0.15 | $76.4M | $79.4M |
| 2026-04-02 | -0.11 | -0.07 | $76.8M | $78.4M |
| 2026-07-14 | -0.11 | -0.07 | $80.2M | $86.6M |
| 2026-10-08 | -0.11 | -0.04 | $80.5M | $80.9M |
| 2027-01-06Upcoming | -0.10 | — | $84.3M | — |
Disclaimer — Informational only — not investment advice. Insider transaction data is sourced from SEC Form 4 filings; market data from public feeds and may be delayed. The Insider Score is a proprietary score for research purposes and does not predict future performance. Always do your own research.